Novartis AG ADR (NVS)vsARS Pharmaceuticals, Inc (SPRY)
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
SPRY
ARS Pharmaceuticals, Inc
$4.76
-5.93%
HEALTHCARE · Cap: $558.89M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 48386% more annual revenue ($56.69B vs $116.93M). NVS leads profitability with a 22.5% profit margin vs -184.2%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
SPRY
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Intrinsic value data unavailable for SPRY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Revenue surging 114.2% year-over-year
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Trading at 36.6x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : SPRY
The strongest argument for SPRY centers on Revenue Growth. Revenue growth of 114.2% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : SPRY
The primary concerns for SPRY are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 13.72 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a value stock while SPRY is a hypergrowth play — different risk/reward profiles.
SPRY carries more volatility with a beta of 1.00 — expect wider price swings.
SPRY is growing revenue faster at 114.2% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 31/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →ARS Pharmaceuticals, Inc
HEALTHCARE · BIOTECHNOLOGY · USA
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine aerosol with absorption technology for patients and their families at risk of severe allergic reactions to food, medication, and insect stings. The company is headquartered in San Diego, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?